Literature DB >> 17410193

Class I HDAC SNP analysis in healthy donors compared to AML patients.

C-L Dransfeld, M Schaich, A D Ho, C Thiede, G Ehninger, U Mahlknecht.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17410193     DOI： 10.1038/sj.leu.2404673

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.

Authors:  Jianbiao Zhou; Chonglei Bi; Wee-Joo Chng; Lip-Lee Cheong; Shaw-Cheng Liu; Sylvia Mahara; Kian-Ghee Tay; Qi Zeng; Jie Li; Ke Guo; Cheng Peow Bobby Tan; Hanry Yu; Daniel H Albert; Chien-Shing Chen
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

2.  The Role of HDACs as Leukemia Therapy Targets using HDI.

Authors:  Ahmad Ahmadzadeh; Elahe Khodadi; Mohammad Shahjahani; Jessika Bertacchini; Tina Vosoughi; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.